Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
International Aids Society to hold a virtual conference » 04:55
07/09/20
07/09
04:55
07/09/20
04:55
ABT

Abbott

$92.57 /

+0.21 (+0.23%)

, BDX

Becton Dickinson

$252.65 /

+1.24 (+0.49%)

, GILD

Gilead

$75.63 /

-0.84 (-1.10%)

, HOLX

Hologic

$57.58 /

+0.72 (+1.27%)

, MRK

Merck

$77.87 /

-0.77 (-0.98%)

, OSUR

OraSure

$13.36 /

+0.37 (+2.85%)

23rd International AIDS…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
ABT Abbott
$92.57 /

+0.21 (+0.23%)

BDX Becton Dickinson
$252.65 /

+1.24 (+0.49%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

HOLX Hologic
$57.58 /

+0.72 (+1.27%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

OSUR OraSure
$13.36 /

+0.37 (+2.85%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
06/15/20 Piper Sandler
Abbott approval narrows competitive gap to DexCom, says Piper Sandler
06/11/20 UBS
Abbott's COVID-19 testing positive contributor, says UBS
06/09/20 Barrington
Surmodics price target raised to $62 from $56 at Barrington
BDX Becton Dickinson
$252.65 /

+1.24 (+0.49%)

04:47 Today Barclays
Becton Dickinson upgraded to Overweight from Equal Weight at Barclays
07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
07/02/20 Wells Fargo
Becton rapid antigen COVID test may be available very soon, says Wells Fargo
06/25/20 Raymond James
Becton Dickinson price target lowered to $265 from $290 at Raymond James
GILD Gilead
$75.63 /

-0.84 (-1.10%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
HOLX Hologic
$57.58 /

+0.72 (+1.27%)

07/02/20 Needham
Hologic price target raised to $64 from $60 at Needham
06/30/20 Cowen
Hologic helped by COVID testing, Cowen upgrades to Outperform
06/30/20 Cowen
Hologic upgraded to Outperform from Market Perform at Cowen
06/16/20 BTIG
Hologic price target raised to $60 from $54 at BTIG
MRK Merck
$77.87 /

-0.77 (-0.98%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
OSUR OraSure
$13.36 /

+0.37 (+2.85%)

06/25/20 Lake Street
OraSure initiated with a Buy at Lake Street
04/21/20 Stephens
OraSure resumed with an Equal Weight at Stephens
ABT Abbott
$92.57 /

+0.21 (+0.23%)

BDX Becton Dickinson
$252.65 /

+1.24 (+0.49%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

HOLX Hologic
$57.58 /

+0.72 (+1.27%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

OSUR OraSure
$13.36 /

+0.37 (+2.85%)

  • 03
    Jun
  • 21
    May
ABT Abbott
$92.57 /

+0.21 (+0.23%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

BDX Becton Dickinson
$252.65 /

+1.24 (+0.49%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

HOLX Hologic
$57.58 /

+0.72 (+1.27%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

OSUR OraSure
$13.36 /

+0.37 (+2.85%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

HOLX Hologic
$57.58 /

+0.72 (+1.27%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

Yesterday
On The Fly
Fly Intel: Wall Street's top stories for Wednesday » 16:18
07/08/20
07/08
16:18
07/08/20
16:18
LEVI

Levi Strauss

$12.68 /

-1.195 (-8.62%)

, FB

Facebook

$243.58 /

+2.51 (+1.04%)

, BIIB

Biogen

$280.15 /

+11.97 (+4.46%)

, ALL

Allstate

$88.20 /

-4.38 (-4.73%)

, NGHC

National General

$33.73 /

+13.29 (+65.02%)

, TWTR

Twitter

$35.39 /

+2.41 (+7.31%)

, MRNA

Moderna

$61.58 /

+0.5 (+0.82%)

, GM

General Motors

$24.93 /

-0.19 (-0.76%)

, FCAU

Fiat Chrysler

$9.99 /

-0.09 (-0.89%)

, XENT

Intersect ENT

$17.98 /

+4.07 (+29.26%)

, MDT

Medtronic

$91.64 /

-0.05 (-0.05%)

, NKLA

Nikola

$54.03 /

+13.78 (+34.24%)

, GILT

Gilat Satellite

$5.20 /

-0.905 (-14.82%)

, CMTL

Comtech

$15.87 /

+0.32 (+2.06%)

Stocks continue to rise…

Open Full Text

ShowHide Related Items >><<
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

NGHC National General
$33.73 /

+13.29 (+65.02%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

06/16/20 Exane BNP Paribas
Levi Strauss initiated with an Outperform at Exane BNP Paribas
04/09/20 Guggenheim
Levi Strauss price target lowered to $16 from $26 at Guggenheim
04/08/20 Citi
Levi Strauss has ample liquidity and remains 'strong brand,' says Citi
03/18/20 BofA
Levi Strauss downgraded to Neutral with $15 price target at BofA
FB Facebook
$243.58 /

+2.51 (+1.04%)

07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
07/01/20 Monness Crespi
Facebook has opportunity to emerge from crisis stronger, says Monness Crespi
07/01/20 Goldman Sachs
Facebook checks show limited impact from ad boycott, says Goldman Sachs
06/30/20 Morgan Stanley
Morgan Stanley says buy Facebook amid boycott-driven weakness
BIIB Biogen
$280.15 /

+11.97 (+4.46%)

07/08/20 Credit Suisse
Biogen submits Aducanumab BLA, upside possible near-term, says Credit Suisse
07/08/20 Stifel
Biogen submission of Aducanumab BLA 'an incremental positive,' says Stifel
07/08/20 Goldman Sachs
Goldman says Biogen BLA submission for Alzheimer's drug an incremental positive
07/08/20 Jefferies
Biogen likely to get Priority Review for aducanumab, says Jefferies
ALL Allstate
$88.20 /

-4.38 (-4.73%)

07/08/20 William Blair
National General downgraded to Market Perform from Outperform at William Blair
07/08/20 B. Riley FBR
National General price target raised to $34.50 from $28 at B. Riley FBR
06/25/20
Fly Intel: Top five analyst upgrades
06/25/20 Credit Suisse
Allstate upgraded to Neutral from Underperform at Credit Suisse
NGHC National General
$33.73 /

+13.29 (+65.02%)

04/08/20
Fly Intel: Top five analyst initiations
04/08/20 JPMorgan
National General initiated with a Neutral at JPMorgan
TWTR Twitter
$35.39 /

+2.41 (+7.31%)

07/08/20 Rosenblatt
Rosenblatt says 'highly unlikely' Twitter considering paid subscription tiers
06/29/20 Stifel
Stifel says Facebook sales won't be materially hurt unless ad boycott broadens
06/29/20 JPMorgan
Facebook estimates not at risk from ad boycott, says JPMorgan
MRNA Moderna
$61.58 /

+0.5 (+0.82%)

07/08/20 Piper Sandler
Piper reiterates $100 target on Moderna after Phase II study enrolled
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
GM General Motors
$24.93 /

-0.19 (-0.76%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
General Motors price target raised to $33 from $29 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

06/30/20 UBS
Fiat Chrysler price target raised to EUR 9 from EUR 6 at UBS
06/22/20 Redburn
Fiat Chrysler upgraded to Buy from Neutral at Redburn
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

07/08/20 Oppenheimer
Takeout bid of $17 for Intersect ENT would be 'reasonable,' says Oppenheimer
06/23/20 Oppenheimer
Intersect ENT initiated with a Perform at Oppenheimer
06/09/20 SVB Leerink
Intersect ENT C-code issuance has 'mixed implications,' says SVB Leerink
06/09/20 Piper Sandler
Intersect ENT's C-Code approval adds access to 40M lives, says Piper Sandler
MDT Medtronic
$91.64 /

-0.05 (-0.05%)

06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
06/30/20 Piper Sandler
United Health coverage a 'clear positive' for Tandem, says Piper Sandler
06/18/20 Argus
Medtronic has strong growth opportunities, says Argus
NKLA Nikola
$54.03 /

+13.78 (+34.24%)

07/08/20
Fly Intel: Top five analyst upgrades
07/08/20 JPMorgan
JPMorgan upgrades Nikola to Overweight after 40% July selloff
07/08/20 JPMorgan
Nikola upgraded to Overweight from Neutral at JPMorgan
07/07/20 RBC Capital
Nikola initiated with a Sector Perform at RBC Capital
GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

06/04/20 Northland
Comtech price target lowered to $24 from $27 at Northland
03/31/20 Citi
Comtech price target lowered to $17 from $34 at Citi
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NGHC National General
$33.73 /

+13.29 (+65.02%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

  • 19
    May
  • 12
    Feb
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

Hot Stocks
Gilead starts Phase 1a trial of inhaled remdesivir in healthy volunteers » 14:31
07/08/20
07/08
14:31
07/08/20
14:31
GILD

Gilead

$75.11 /

-1.36 (-1.78%)

Gilead Sciences a…

Gilead Sciences a statement from Merdad Parsey, its Chief Medical Officer: "Since the beginning of the COVID-19 pandemic, Gilead has mobilized its deep expertise in virology to rapidly assess the potent investigational antiviral, remdesivir, to evaluate its safety and efficacy as a potential treatment option for patients with COVID-19. With promising data emerging from the randomized, clinical trials of intravenous remdesivir administered to hospitalized patients, it became clear that efforts were needed to investigate the drug's potential in the outpatient setting. Significant research efforts have been undertaken to deliver remdesivir in an inhaled, nebulized format. We are pleased to announce the initiation of a Phase 1a clinical study to evaluate the safety, tolerability and pharmacokinetics of an investigational, inhaled solution of remdesivir in healthy volunteers. Based on current scientific understanding, the upper respiratory tract is the most prevalent site of SARS-CoV-2 infection early in disease. Delivering remdesivir directly to the primary site of infection with a nebulized, inhaled solution may enable more targeted and accessible administration in non-hospitalized patients and potentially lower systemic exposure to the drug. This randomized, placebo-controlled trial will enroll approximately 60 healthy individuals aged 18-45 in the United States to form the basis for further clinical study of the inhaled drug, particularly in patients whose disease has not progressed to require hospitalization."

ShowHide Related Items >><<
GILD Gilead
$75.11 /

-1.36 (-1.78%)

GILD Gilead
$75.11 /

-1.36 (-1.78%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
GILD Gilead
$75.11 /

-1.36 (-1.78%)

GILD Gilead
$75.11 /

-1.36 (-1.78%)

GILD Gilead
$75.11 /

-1.36 (-1.78%)

GILD Gilead
$75.11 /

-1.36 (-1.78%)

Recommendations
Piper reiterates $100 target on Moderna after Phase II study enrolled » 11:38
07/08/20
07/08
11:38
07/08/20
11:38
MRNA

Moderna

$59.65 /

-1.43 (-2.34%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Moderna with a $100 price target after the company completed enrollment of 600 subjects in the Phase II study of SARS-CoV-2 vaccine mRNA-1273. The stock in midday trading is down $1.03 to $60.06. Separately, the National Institutes of Health has also completed enrollment of the older adult cohorts with results expected to be published soon, the analyst adds. In addition, Tenthoff finds it important that the National Institute of Allergy and Infectious Diseases/NIH partnered Phase III protocol has been finalized based on FDA feedback and is on-track to begin in July.

ShowHide Related Items >><<
MRNA Moderna
$59.65 /

-1.43 (-2.34%)

MRNA Moderna
$59.65 /

-1.43 (-2.34%)

07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/26/20 Morgan Stanley
Morgan Stanley says Axios overstates contention on Moderna-NIH vaccine ownership
MRNA Moderna
$59.65 /

-1.43 (-2.34%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$59.65 /

-1.43 (-2.34%)

MRNA Moderna
$59.65 /

-1.43 (-2.34%)

MRNA Moderna
$59.65 /

-1.43 (-2.34%)

Hot Stocks
Moderna says COVID-19 Phase 3 study protocol finalized with FDA » 09:48
07/08/20
07/08
09:48
07/08/20
09:48
MRNA

Moderna

$60.88 /

-0.2 (-0.33%)

, CTLT

Catalent

$74.13 /

+0.43 (+0.58%)

Moderna said it has…

Moderna said it has finalized the Phase 3 study protocol based on feedback from the U.S. Food and Drug Administration. "The randomized, 1:1 placebo-controlled trial is expected to include approximately 30,000 participants at the 100 microgram dose level in the U.S. and is expected to be conducted in collaboration with NIAID, subject to regulatory approval. Moderna has completed manufacture of vaccine required to start the Phase 3 study. With the Phase 3 dose at 100 undefined, the Company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021 from the company's internal U.S. manufacturing site and strategic collaboration with Lonza. In addition, Moderna recently announced a collaboration with Catalent for large-scale, commercial fill-finish manufacturing of mRNA-1273 at Catalent's biologics facility in Indiana," Moderna stated.

ShowHide Related Items >><<
MRNA Moderna
$60.88 /

-0.2 (-0.33%)

CTLT Catalent
$74.13 /

+0.43 (+0.58%)

MRNA Moderna
$60.88 /

-0.2 (-0.33%)

07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/26/20 Morgan Stanley
Morgan Stanley says Axios overstates contention on Moderna-NIH vaccine ownership
CTLT Catalent
$74.13 /

+0.43 (+0.58%)

06/26/20 Baird
Catalent price target raised to $80 from $74 at Baird
06/25/20 Argus
Catalent initiated with a Buy at Argus
05/06/20 Baird
Catalent price target raised to $74 from $63 at Baird
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
MRNA Moderna
$60.88 /

-0.2 (-0.33%)

CTLT Catalent
$74.13 /

+0.43 (+0.58%)

  • 11
    Jun
  • 19
    May
  • 12
    Feb
  • 04
    Feb
MRNA Moderna
$60.88 /

-0.2 (-0.33%)

CTLT Catalent
$74.13 /

+0.43 (+0.58%)

MRNA Moderna
$60.88 /

-0.2 (-0.33%)

CTLT Catalent
$74.13 /

+0.43 (+0.58%)

MRNA Moderna
$60.88 /

-0.2 (-0.33%)

Hot Stocks
Moderna completes enrollment of Phase 2 study of COVID-19 mRNA vaccine » 09:47
07/08/20
07/08
09:47
07/08/20
09:47
MRNA

Moderna

$60.27 /

-0.81 (-1.33%)

Moderna announced that it…

Moderna announced that it has completed enrollment for both cohorts of the Phase 2 study of its vaccine candidate, mRNA-1273, against COVID-19. mRNA-1273 is Moderna's second mRNA vaccine for an infectious disease to complete enrollment of a Phase 2 study, following the company's CMV Phase 2 study, which was fully enrolled on March 3, the company stated. On June 11, "13 days after the first participant was dosed," the company announced that the cohort of healthy younger adults ages 18-55 and the sentinel group of older adults ages 55 years and above in the Phase 2 study of mRNA-1273 was complete. The company also announced that the cohorts of older adults and elderly adults in NIH-led Phase 1 study have completed enrollment. Results are expected to be published once available.

ShowHide Related Items >><<
MRNA Moderna
$60.27 /

-0.81 (-1.33%)

MRNA Moderna
$60.27 /

-0.81 (-1.33%)

07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/26/20 Morgan Stanley
Morgan Stanley says Axios overstates contention on Moderna-NIH vaccine ownership
MRNA Moderna
$60.27 /

-0.81 (-1.33%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$60.27 /

-0.81 (-1.33%)

MRNA Moderna
$60.27 /

-0.81 (-1.33%)

MRNA Moderna
$60.27 /

-0.81 (-1.33%)

Hot Stocks
Moderna says completed enrollment of Phase 2 COVID-19 vaccine study » 09:36
07/08/20
07/08
09:36
07/08/20
09:36
MRNA

Moderna

$61.08 /

+1.94 (+3.28%)

Moderna posted on its…

Moderna posted on its official Twitter feed: "We have completed enrollment of our Phase 2 study of mRNA-1273, our #mRNA #vaccine candidate against COVID-19." Reference Link

ShowHide Related Items >><<
MRNA Moderna
$61.08 /

+1.94 (+3.28%)

MRNA Moderna
$61.08 /

+1.94 (+3.28%)

07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/26/20 Morgan Stanley
Morgan Stanley says Axios overstates contention on Moderna-NIH vaccine ownership
MRNA Moderna
$61.08 /

+1.94 (+3.28%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$61.08 /

+1.94 (+3.28%)

MRNA Moderna
$61.08 /

+1.94 (+3.28%)

MRNA Moderna
$61.08 /

+1.94 (+3.28%)

Conference/Events
International Aids Society to hold a virtual conference » 04:55
07/08/20
07/08
04:55
07/08/20
04:55
ABT

Abbott

$92.36 /

-0.62 (-0.67%)

, BDX

Becton Dickinson

$251.41 /

+1.035 (+0.41%)

, GILD

Gilead

$76.47 /

-0.31 (-0.40%)

, HOLX

Hologic

$56.86 /

-0.99 (-1.71%)

, MRK

Merck

$78.64 /

-0.95 (-1.19%)

, OSUR

OraSure

$12.99 /

+0.375 (+2.97%)

23rd International AIDS…

23rd International AIDS Virtual Conference: AIDS 2020 will be held on July 6-10. Webcast Link

ShowHide Related Items >><<
OSUR OraSure
$12.99 /

+0.375 (+2.97%)

MRK Merck
$78.64 /

-0.95 (-1.19%)

HOLX Hologic
$56.86 /

-0.99 (-1.71%)

GILD Gilead
$76.47 /

-0.31 (-0.40%)

BDX Becton Dickinson
$251.41 /

+1.035 (+0.41%)

ABT Abbott
$92.36 /

-0.62 (-0.67%)

ABT Abbott
$92.36 /

-0.62 (-0.67%)

07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
06/15/20 Piper Sandler
Abbott approval narrows competitive gap to DexCom, says Piper Sandler
06/11/20 UBS
Abbott's COVID-19 testing positive contributor, says UBS
06/09/20 Barrington
Surmodics price target raised to $62 from $56 at Barrington
BDX Becton Dickinson
$251.41 /

+1.035 (+0.41%)

07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
07/02/20 Wells Fargo
Becton rapid antigen COVID test may be available very soon, says Wells Fargo
06/25/20 Raymond James
Becton Dickinson price target lowered to $265 from $290 at Raymond James
06/01/20
Fly Intel: Top five analyst initiations
GILD Gilead
$76.47 /

-0.31 (-0.40%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
HOLX Hologic
$56.86 /

-0.99 (-1.71%)

07/02/20 Needham
Hologic price target raised to $64 from $60 at Needham
06/30/20 Cowen
Hologic helped by COVID testing, Cowen upgrades to Outperform
06/30/20 Cowen
Hologic upgraded to Outperform from Market Perform at Cowen
06/16/20 BTIG
Hologic price target raised to $60 from $54 at BTIG
MRK Merck
$78.64 /

-0.95 (-1.19%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
OSUR OraSure
$12.99 /

+0.375 (+2.97%)

06/25/20 Lake Street
OraSure initiated with a Buy at Lake Street
04/21/20 Stephens
OraSure resumed with an Equal Weight at Stephens
OSUR OraSure
$12.99 /

+0.375 (+2.97%)

MRK Merck
$78.64 /

-0.95 (-1.19%)

HOLX Hologic
$56.86 /

-0.99 (-1.71%)

GILD Gilead
$76.47 /

-0.31 (-0.40%)

BDX Becton Dickinson
$251.41 /

+1.035 (+0.41%)

ABT Abbott
$92.36 /

-0.62 (-0.67%)

  • 03
    Jun
  • 21
    May
MRK Merck
$78.64 /

-0.95 (-1.19%)

GILD Gilead
$76.47 /

-0.31 (-0.40%)

ABT Abbott
$92.36 /

-0.62 (-0.67%)

OSUR OraSure
$12.99 /

+0.375 (+2.97%)

MRK Merck
$78.64 /

-0.95 (-1.19%)

HOLX Hologic
$56.86 /

-0.99 (-1.71%)

GILD Gilead
$76.47 /

-0.31 (-0.40%)

BDX Becton Dickinson
$251.41 /

+1.035 (+0.41%)

ABT Abbott
$92.36 /

-0.62 (-0.67%)

MRK Merck
$78.64 /

-0.95 (-1.19%)

HOLX Hologic
$56.86 /

-0.99 (-1.71%)

GILD Gilead
$76.47 /

-0.31 (-0.40%)

ABT Abbott
$92.36 /

-0.62 (-0.67%)

Tuesday
Hot Stocks
Arcus Biosciences names Bob Goeltz CFO » 16:11
07/07/20
07/07
16:11
07/07/20
16:11
RCUS

Arcus Biosciences

$25.30 /

+1.26 (+5.24%)

, UBX

Unity Biotechnology

$8.10 /

-0.77 (-8.68%)

, CTMX

CytomX Therapeutics

$8.22 /

+0.04 (+0.49%)

, GILD

Gilead

$76.40 /

-0.385 (-0.50%)

Arcus Biosciences (RCUS)…

Arcus Biosciences (RCUS) announced that Bob Goeltz will join Arcus as Chief Financial Officer on August 1, 2020. Goeltz most recently served as Chief Financial Officer and Senior Vice President of UNITY Biotechnology (UBX) and immediately before that as Chief Financial Officer of CytomX Therapeutics (CTMX). "Following the recent announcement of our 10-year collaboration with Gilead (GILD) and successful $348 million financial offering, combined with our growing portfolio of programs, I am confident Bob will play an integral role in advancing Arcus through our next phase of growth towards commercialization and beyond," said Terry Rosen, Ph.D., Chief Executive Officer of Arcus. "Bob's experience in navigating the strategic and operational decisions necessary to transition the opportunities derived from an intense, deep and innovative R&D effort through the commercialization process to broadly benefit patients will be central to Arcus's future success. With the potential to have three molecules in registrational studies in 2021, a prolific discovery team and a uniquely enabling and nascent alliance with Gilead, Bob joins Arcus at a seminal inflection point, with the opportunity to make Arcus's vision of creating, developing and commercializing innovative and curative therapies for cancer a reality."

ShowHide Related Items >><<
UBX Unity Biotechnology
$8.10 /

-0.77 (-8.68%)

RCUS Arcus Biosciences
$25.30 /

+1.26 (+5.24%)

GILD Gilead
$76.40 /

-0.385 (-0.50%)

CTMX CytomX Therapeutics
$8.22 /

+0.04 (+0.49%)

RCUS Arcus Biosciences
$25.30 /

+1.26 (+5.24%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
UBX Unity Biotechnology
$8.10 /

-0.77 (-8.68%)

12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
CTMX CytomX Therapeutics
$8.22 /

+0.04 (+0.49%)

06/01/20 Jefferies
Jefferies 'underwhelmed' by CytomX presentations at ASCO, downgrades to Hold
06/01/20 Jefferies
CytomX Therapeutics downgraded to Hold from Buy at Jefferies
05/29/20 Piper Sandler
CytomX ASCO data sets point torwards Probody validation, says Piper Sandler
05/14/20 H.C. Wainwright
CytomX Therapeutics price target lowered to $12 from $16 at H.C. Wainwright
GILD Gilead
$76.40 /

-0.385 (-0.50%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
UBX Unity Biotechnology
$8.10 /

-0.77 (-8.68%)

RCUS Arcus Biosciences
$25.30 /

+1.26 (+5.24%)

GILD Gilead
$76.40 /

-0.385 (-0.50%)

CTMX CytomX Therapeutics
$8.22 /

+0.04 (+0.49%)

  • 29
    May
RCUS Arcus Biosciences
$25.30 /

+1.26 (+5.24%)

GILD Gilead
$76.40 /

-0.385 (-0.50%)

RCUS Arcus Biosciences
$25.30 /

+1.26 (+5.24%)

GILD Gilead
$76.40 /

-0.385 (-0.50%)

CTMX CytomX Therapeutics
$8.22 /

+0.04 (+0.49%)

RCUS Arcus Biosciences
$25.30 /

+1.26 (+5.24%)

GILD Gilead
$76.40 /

-0.385 (-0.50%)

Conference/Events
International Aids Society to hold a virtual conference » 09:24
07/07/20
07/07
09:24
07/07/20
09:24
ABT

Abbott

$92.98 /

+0.73 (+0.79%)

, BDX

Becton Dickinson

$250.38 /

+5.285 (+2.16%)

, GILD

Gilead

$76.78 /

+0.47 (+0.62%)

, HOLX

Hologic

$57.85 /

-0.02 (-0.03%)

, MRK

Merck

$79.59 /

+0.8 (+1.02%)

, OSUR

OraSure

$12.62 /

+0.605 (+5.04%)

23rd International AIDS…

23rd International AIDS Virtual Conference: AIDS 2020 will be held on July 6-10. Webcast Link

ShowHide Related Items >><<
OSUR OraSure
$12.62 /

+0.605 (+5.04%)

MRK Merck
$79.59 /

+0.8 (+1.02%)

HOLX Hologic
$57.85 /

-0.02 (-0.03%)

GILD Gilead
$76.78 /

+0.47 (+0.62%)

BDX Becton Dickinson
$250.38 /

+5.285 (+2.16%)

ABT Abbott
$92.98 /

+0.73 (+0.79%)

ABT Abbott
$92.98 /

+0.73 (+0.79%)

07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
06/15/20 Piper Sandler
Abbott approval narrows competitive gap to DexCom, says Piper Sandler
06/11/20 UBS
Abbott's COVID-19 testing positive contributor, says UBS
06/09/20 Barrington
Surmodics price target raised to $62 from $56 at Barrington
BDX Becton Dickinson
$250.38 /

+5.285 (+2.16%)

07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
07/02/20 Wells Fargo
Becton rapid antigen COVID test may be available very soon, says Wells Fargo
06/25/20 Raymond James
Becton Dickinson price target lowered to $265 from $290 at Raymond James
06/01/20
Fly Intel: Top five analyst initiations
GILD Gilead
$76.78 /

+0.47 (+0.62%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
HOLX Hologic
$57.85 /

-0.02 (-0.03%)

07/02/20 Needham
Hologic price target raised to $64 from $60 at Needham
06/30/20 Cowen
Hologic helped by COVID testing, Cowen upgrades to Outperform
06/30/20 Cowen
Hologic upgraded to Outperform from Market Perform at Cowen
06/16/20 BTIG
Hologic price target raised to $60 from $54 at BTIG
MRK Merck
$79.59 /

+0.8 (+1.02%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
OSUR OraSure
$12.62 /

+0.605 (+5.04%)

06/25/20 Lake Street
OraSure initiated with a Buy at Lake Street
04/21/20 Stephens
OraSure resumed with an Equal Weight at Stephens
OSUR OraSure
$12.62 /

+0.605 (+5.04%)

MRK Merck
$79.59 /

+0.8 (+1.02%)

HOLX Hologic
$57.85 /

-0.02 (-0.03%)

GILD Gilead
$76.78 /

+0.47 (+0.62%)

BDX Becton Dickinson
$250.38 /

+5.285 (+2.16%)

ABT Abbott
$92.98 /

+0.73 (+0.79%)

  • 03
    Jun
  • 21
    May
MRK Merck
$79.59 /

+0.8 (+1.02%)

GILD Gilead
$76.78 /

+0.47 (+0.62%)

ABT Abbott
$92.98 /

+0.73 (+0.79%)

OSUR OraSure
$12.62 /

+0.605 (+5.04%)

MRK Merck
$79.59 /

+0.8 (+1.02%)

HOLX Hologic
$57.85 /

-0.02 (-0.03%)

GILD Gilead
$76.78 /

+0.47 (+0.62%)

BDX Becton Dickinson
$250.38 /

+5.285 (+2.16%)

ABT Abbott
$92.98 /

+0.73 (+0.79%)

MRK Merck
$79.59 /

+0.8 (+1.02%)

HOLX Hologic
$57.85 /

-0.02 (-0.03%)

GILD Gilead
$76.78 /

+0.47 (+0.62%)

ABT Abbott
$92.98 /

+0.73 (+0.79%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.